Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma.

Adam Yuh Lin, Jonathan Scott Rink, Reem Karmali, Jiahui Xu, Masha Kocherginsky, Colby Shad Thaxton, Leo I Gordon

Nanomedicine : nanotechnology, biology, and medicine 2020 Nov

filter terms:

CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects. Copyright © 2020 Elsevier Inc. All rights reserved.

Citation

Adam Yuh Lin, Jonathan Scott Rink, Reem Karmali, Jiahui Xu, Masha Kocherginsky, Colby Shad Thaxton, Leo I Gordon. Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma. Nanomedicine : nanotechnology, biology, and medicine. 2020 Nov;30:102290